Clinical Trial Update: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Bendamustine plus Rituximab for relapsed or progressive marginal zone B-cell lymphoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Marginal Zone B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2026-04-22